Zobrazeno 1 - 10
of 62
pro vyhledávání: '"W. E. Aulitzky"'
Autor:
Thomas F. Schulz, L. Ostberg, P. Grass, Christoph Huber, M. Scriba, K. Larcher, Dietger Niederwieser, Herbert Tilg, M. Mach, M. P. Dierich, W. E. Aulitzky, A. C. Stern, J. Martindale
The safety and pharmacokinetics of the two neutralizing human IgG1 monoclonal antibodies to cytomegalovirus (CMV) SDZ 89-104 and 89-109 in bone marrow transplant (BMT) recipients was assessed in an open phase I trial. Thirteen patients, 8 seropositiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce9d4519668cebb2d635c80395658690
http://doc.rero.ch/record/296463/files/163-6-1344.pdf
http://doc.rero.ch/record/296463/files/163-6-1344.pdf
Autor:
Jochen Schütte, Frank Fleischer, Dirk Strumberg, Klaus Mross, M Merger, W E Aulitzky, Roland M Schmid, Max E. Scheulen, S Hollerbach, Gerd Munzert, Christian Dittrich
Publikováno v:
British Journal of Cancer
Background: BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas. Methods: The study employed a two-stage design. Randomised first-line patients received BI 2536 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e381ab55c8bf745bba7ffc5c91bddc31
http://europepmc.org/articles/PMC3394983
http://europepmc.org/articles/PMC3394983
Autor:
F, Stölzel, M, Pfirrmann, W E, Aulitzky, M, Kaufmann, H, Bodenstein, M, Bornhäuser, C, Röllig, M, Kramer, B, Mohr, U, Oelschlägel, N, Schmitz, S, Soucek, C, Thiede, G, Ehninger, M, Schaich, H, Rueckle-Lanz
Publikováno v:
Leukemia. 25:420-428
Patients with secondary acute myeloid leukemia (sAML) are generally thought to have a poor prognosis. As there are no prognostic risk stratification models for patients with sAML available, the aim of this study was to obtain a scoring system. Progno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160b0de155189c1b89d00169dad3f986
https://doi.org/10.1038/leu.2010.279
https://doi.org/10.1038/leu.2010.279
Publikováno v:
Zeitschrift für Palliativmedizin. 10:51-54
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::961af403afcfad8b712646caffd5413d
https://doi.org/10.1055/s-0028-1090170
https://doi.org/10.1055/s-0028-1090170
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 121:600-604
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d635904d282ad19bff75526f0a239e8a
https://doi.org/10.1055/s-2008-1043045
https://doi.org/10.1055/s-2008-1043045
Autor:
W. E. Aulitzky, M. Kaufmann
Publikováno v:
Der Urologe A. 43:85-94
Beim Nierenzellkarzinom hat sich die Uberlebenszeit der Patienten in fruhen Stadien durch verbesserte chirurgische Therapie deutlich erhoht. Fur Patienten mit fortgeschrittenen Stadien hat sich die Prognose aber nur unwesentlich verandert. Behandlung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef7f5a2cda96402c7e7fc1137185bc83
https://doi.org/10.1007/s00120-003-0502-5
https://doi.org/10.1007/s00120-003-0502-5
Autor:
L, Bergmann, L, Maute, G, Heil, J, Rüssel, E, Weidmann, D, Köberle, S, Fuxius, K, Weigang-Köhler, W E, Aulitzky, B, Wörmann, G, Hartung, B, Moritz, L, Edler, I, Burkholder, M E, Scheulen, H, Richly
Publikováno v:
European journal of cancer (Oxford, England : 1990). 51(1)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common malignant tumours and is still associated with a poor prognosis in advanced disease. To improve the standard therapy with gemcitabine, we initiated a prospective randomised phase-II tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9abb07764ab13b26e2c409c8a22e0d60
https://pubmed.ncbi.nlm.nih.gov/25459392
https://pubmed.ncbi.nlm.nih.gov/25459392
Publikováno v:
The Journal of Immunology. 150:4687-4692
This study was undertaken to determine whether IFN induce IL-1 receptor antagonist (IL-1Ra), a specific inhibitor of IL-1. Plasma samples were obtained from healthy volunteers (n = 5) and patients with chronic hepatitis C (n = 5) treated with IFN-alp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3359542280c0ee37b3cf3c132723eab
https://doi.org/10.4049/jimmunol.150.10.4687
https://doi.org/10.4049/jimmunol.150.10.4687
Publikováno v:
Die Onkologie ISBN: 9783540797241
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e52bf385809f76ffd451fa139560bcbd
https://doi.org/10.1007/978-3-540-79725-8_55
https://doi.org/10.1007/978-3-540-79725-8_55